PCSK9 inhibitors - clinical applications.
作者信息
Schmidli Robert
机构信息
Department of Endocrinology, Canberra Hospital.
出版信息
Aust Prescr. 2016 Oct;39(5):168-170. doi: 10.18773/austprescr.2016.061. Epub 2016 Oct 1.
Abstract
摘要
相似文献
1
PCSK9 inhibitors - clinical applications.前蛋白转化酶枯草溶菌素9抑制剂——临床应用
Aust Prescr. 2016 Oct;39(5):168-170. doi: 10.18773/austprescr.2016.061. Epub 2016 Oct 1.
2
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.前蛋白转化酶枯草溶菌素/克新9型（PCSK9）抑制剂：当前观点与未来展望。
Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):853-62. doi: 10.1016/j.numecd.2016.05.006. Epub 2016 May 30.
3
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.抑制前蛋白转化酶枯草溶菌素 9（PCSK9）用玻卡鲁胺对高胆固醇血症患者脂蛋白颗粒的影响。
Clin Ther. 2017 Nov;39(11):2243-2259.e5. doi: 10.1016/j.clinthera.2017.09.009. Epub 2017 Oct 14.
4
[Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].[严重高胆固醇血症——何时使用前蛋白转化酶枯草溶菌素9型蛋白酶抑制剂（PCSK9抑制剂）？波兰心脏病学会专家组声明]
Kardiol Pol. 2016;74(4):394-8. doi: 10.5603/KP.2016.0051.
5
From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.从脂蛋白吸附术到前蛋白转化酶枯草溶菌素 9 抑制剂：对心血管疾病患者的低密度脂蛋白胆固醇和 C 反应蛋白水平的影响。
Eur J Prev Cardiol. 2018 Nov;25(17):1843-1851. doi: 10.1177/2047487318792626. Epub 2018 Jul 30.
6
Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events.前蛋白转化酶枯草溶菌素/kexin 9型抑制剂用于降低心血管事件
Am J Health Syst Pharm. 2018 Jun 1;75(11):747-754. doi: 10.2146/ajhp170707.
7
Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.前蛋白转化酶枯草杆菌蛋白酶/kexin 9型抑制剂治疗常染色体隐性高胆固醇血症——简要报告
Arterioscler Thromb Vasc Biol. 2016 Aug;36(8):1647-50. doi: 10.1161/ATVBAHA.116.307493. Epub 2016 Apr 14.
8
Proprotein Convertase Subtilisin Kexin 9 Inhibitors.前蛋白转化酶枯草杆菌蛋白酶/kexin 9型抑制剂
Cardiol Clin. 2018 May;36(2):241-256. doi: 10.1016/j.ccl.2017.12.006.
9
Vaccine strategies for lowering LDL by immunization against proprotein convertase subtilisin/kexin type 9.通过针对9型前蛋白转化酶枯草杆菌蛋白酶/kexin进行免疫接种来降低低密度脂蛋白的疫苗策略。
Curr Opin Lipidol. 2016 Aug;27(4):345-50. doi: 10.1097/MOL.0000000000000312.
10
The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.前蛋白转化酶枯草溶菌素9型抑制剂在血脂异常管理中的作用
Curr Pharm Des. 2017;23(10):1495-1499. doi: 10.2174/1381612823666170201161631.
引用本文的文献
1
The evolving landscape of PCSK9 inhibition in cancer.PCSK9 抑制在癌症中的不断演变的格局。
Eur J Pharmacol. 2023 Jun 15;949:175721. doi: 10.1016/j.ejphar.2023.175721. Epub 2023 Apr 12.
2
Targeted Strategy in Lipid-Lowering Therapy.降脂治疗中的靶向策略。
Biomedicines. 2022 May 8;10(5):1090. doi: 10.3390/biomedicines10051090.
3
Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition.前蛋白转化酶枯草溶菌素/克新9型（PCSK9）抑制的抗肿瘤活性及分子机制
Naunyn Schmiedebergs Arch Pharmacol. 2022 Jun;395(6):643-658. doi: 10.1007/s00210-022-02200-y. Epub 2022 Mar 21.
4
Alirocumab for hypercholesterolaemia.阿利西尤单抗用于治疗高胆固醇血症。
Aust Prescr. 2019 Feb;42(1):29-31. doi: 10.18773/austprescr.2019.071. Epub 2018 Dec 13.
5
Proprotein convertase inhibition: Paralyzing the cell's master switches.前体蛋白转化酶抑制：使细胞的主开关失灵。
Biochem Pharmacol. 2017 Sep 15;140:8-15. doi: 10.1016/j.bcp.2017.04.027. Epub 2017 Apr 27.
6
Inhibition of PCSK9 protects against radiation-induced damage of prostate cancer cells.抑制前蛋白转化酶枯草溶菌素9可预防辐射诱导的前列腺癌细胞损伤。
Onco Targets Ther. 2017 Apr 12;10:2139-2146. doi: 10.2147/OTT.S129413. eCollection 2017.
7
Evolocumab.依洛尤单抗
Aust Prescr. 2016 Oct;39(5):180-182. doi: 10.18773/austprescr.2016.078. Epub 2016 Oct 1.
本文引用的文献
1
Evolocumab.依洛尤单抗
Aust Prescr. 2016 Oct;39(5):180-182. doi: 10.18773/austprescr.2016.078. Epub 2016 Oct 1.
2
Profile of evolocumab and its potential in the treatment of hyperlipidemia.依洛尤单抗简介及其在治疗高脂血症中的潜力。
Drug Des Devel Ther. 2015 Jun 15;9:3073-82. doi: 10.2147/DDDT.S67498. eCollection 2015.
3
PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a).前蛋白转化酶枯草溶菌素9（PCSK9）抑制作用：发现、当前证据以及对低密度脂蛋白胆固醇（LDL-C）和脂蛋白(a) [Lp(a)]的潜在影响
Cardiovasc Drugs Ther. 2015 Jun;29(3):295-308. doi: 10.1007/s10557-015-6588-3.
4
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.依折麦布联合他汀类药物治疗急性冠脉综合征。
N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3.
5
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.依洛尤单抗降低血脂和心血管事件的疗效和安全性。
N Engl J Med. 2015 Apr 16;372(16):1500-9. doi: 10.1056/NEJMoa1500858. Epub 2015 Mar 15.
6
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.阿利西尤单抗降低血脂和心血管事件的疗效和安全性。
N Engl J Med. 2015 Apr 16;372(16):1489-99. doi: 10.1056/NEJMoa1501031. Epub 2015 Mar 15.
7
Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis.来自 3 个数据源的他汀类药物治疗患者的血脂异常患病率和血脂达标情况：一项回顾性分析。
J Am Heart Assoc. 2012 Dec;1(6):e001800. doi: 10.1161/JAHA.112.001800. Epub 2012 Dec 19.
8
Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.载脂蛋白 B 代谢物单克隆抗体 AMG 145 降低杂合子家族性高胆固醇血症患者低密度脂蛋白胆固醇的作用：载脂蛋白 B 代谢物单克隆抗体 AMG 145 降低杂合子家族性高胆固醇血症患者低密度脂蛋白胆固醇的随机试验（RUTHERFORD）
Circulation. 2012 Nov 13;126(20):2408-17. doi: 10.1161/CIRCULATIONAHA.112.144055. Epub 2012 Nov 5.
9
Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.在正在接受稳定阿托伐他汀治疗的原发性高胆固醇血症患者中，一种枯草溶菌素转化酶/前蛋白转化酶 9 丝氨酸蛋白酶单克隆抗体 SAR236553/REGN727 的安全性和有效性。
J Am Coll Cardiol. 2012 Jun 19;59(25):2344-53. doi: 10.1016/j.jacc.2012.03.007. Epub 2012 Mar 28.
10
Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.非诺贝特治疗对9795例2型糖尿病及代谢综合征各组分患者心血管疾病风险的影响：非诺贝特干预与糖尿病事件降低（FIELD）研究。
Diabetes Care. 2009 Mar;32(3):493-8. doi: 10.2337/dc08-1543. Epub 2008 Nov 4.
Zotero 插件